NCT02998775 is a EARLY_PHASE1 clinical trial of Plasma Sampling in Hepatic Impairment; Renal Impairment, sponsored by Eisai Inc..

Who is sponsoring NCT02998775?

NCT02998775 is sponsored by Eisai Inc..

What drugs are being tested in NCT02998775?

Interventions in NCT02998775: Plasma Sampling.

What condition does NCT02998775 study?

NCT02998775 studies Hepatic Impairment; Renal Impairment.

Is NCT02998775 still recruiting?

NCT02998775 is currently completed. Last updated 7 September 2018.

Last reviewed 2018-09-07 · How we verify

NCT02998775

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

Completed EARLY_PHASE1 Last updated 7 September 2018

What this trial tests

EARLY_PHASE1 trial testing Plasma Sampling in Hepatic Impairment; Renal Impairment in 54 participants. Completed in 8 July 2017.

Timeline

2 December 2016

Primary endpoint
8 July 2017

8 July 2017

Quick facts

Lead sponsor	Eisai Inc.
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	54
Start date	2 December 2016
Primary completion	8 July 2017
Estimated completion	8 July 2017
Sites	3 locations across United States

Drugs / interventions tested

Plasma Sampling — full drug profile →

Conditions studied

Hepatic Impairment; Renal Impairment — all drugs for Hepatic Impairment; Renal Impairment →

Sponsor

Eisai Inc. — full company profile →

Who can join

Adults 18 to 79, any sex, with Hepatic Impairment; Renal Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy participants. The primary objective of the study is to obtain plasma from participants for use in in vitro protein binding studies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Eisai Inc. trials

Trials by the same sponsor.

NCT07493265 — A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy · Phase 2 · not yet recruiting
NCT07308236 — A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants · Phase 1 · recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
NCT06744673 — A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control P · active not recruiting
NCT06602258 — A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02998775 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Inc.
Last refreshed: 7 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02998775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing